Leveraging Visual Outcome Measures to Advance Therapy Development in Neuroimmunologic Disorders
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 15, 2021
- Accepted in final form November 4, 2021
- First Published December 26, 2021.
Author Disclosures
- Jennifer S. Graves, MD, PhD, MAS,
- Frederike Cosima Oertel, MD,
- Anneke Van der Walt, MBChB, PhD,
- Sara Collorone, MD, PhD,
- Elias S. Sotirchos, MD,
- Gorm Pihl-Jensen, PhD,
- Philipp Albrecht, MD,
- E. Ann Yeh, MD,
- Shiv Saidha, MBBCh, MD, MRCPI,
- Jette Frederiksen, MD,
- Scott Douglas Newsome, DO,
- Friedemann Paul, MD;
- on behalf of IMSVISUAL
- Jennifer S. Graves, MD, PhD, MAS,
Novartis, Genentech, Bayer
NONE
NONE
Assistant editor for Neurology 2020-2021 Associate editor for ACTN 2019-2021
NONE
NONE
NONE
NONE
Alexion, BMS
NONE
NONE
1) Octave 2) Biogen 3) EMD Serono
NONE
NONE
1) National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Frederike Cosima Oertel, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
American Academy of Neurology (AAN) National Multiple Sclerosis Society (US) Deutsche Gesellschaft für Neurologie (DGN)
NONE
NONE
NONE
NONE
NONE
NONE
- Anneke Van der Walt, MBChB, PhD,
(1) Alexion scientific advisory board (2) Novartis scientific advisory board (3) NervGen scientific advisory board (4) Biogen scientific advisory board (5) Roche scientific advisory board
NONE
(1) Biogen Idec, Roche, Merck, Novartis Australia - travel support and speaker's honoraria
NONE
NONE
NONE
NONE
NONE
NONE
(1) Employed as the Chief Operating Officer of the MSBase Foundation.
NONE
(1)Biogen Idec;Novartis Australia, Roche
(1) NHMRC Investigator Grant no 1196380:2021-2026; (2) Trish Grant 19-0665,2020-2022, CIA (3) MSRA Project Grant ANZAN MSNI COVID-19 Registry, 2020, CIA (4) NHMRC Project Grant 1142353, 2018-2021, CIB
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sara Collorone, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Rosetrees Trust (MS632) (2) Rosetrees Trust (183425)
NONE
NONE
NONE
NONE
NONE
NONE
- Elias S. Sotirchos, MD,
NONE
NONE
Speaker honoraria: 1) Viela Bio 2) Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institutes of Health (NIH) K23NS117883
NONE
1) National MS Society (NMSS) FP-1607-24999 2) National MS Society (NMSS) TA-1904-33834
NONE
NONE
NONE
NONE
NONE
NONE
- Gorm Pihl-Jensen, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Philipp Albrecht, MD,
(1) Novartis, serving on an advisory board; (2) Biogen, serving on an advisory board; (3) Ipsen, serving on an advisory board; (4) Merck, serving on an advisory board; (5) Merz, serving on an advisory board; (6) Roche, serving on an advisory board; (7) Allergan, serving on an advisory board; (8) Celgene, serving on an advisory board; (9) Janssen Cilag, serving on an advisory board;
NONE
(1) Novartis, travel/accommodation/meeting expenses and speaker honoraria; (2)Teva, travel/accommodation/meeting expenses and speaker honoraria; (3) Biogen, travel/accommodation/meeting expenses and speaker honoraria; (4) Merz Pharmaceuticals, travel/accommodation/meeting expenses, (5) Ipsen, travel/accommodation/meeting expenses; (6) Esai, travel/accommodation/meeting expenses; (7) Glaxo Smith Kline, travel/accommodation/meeting expenses; (8) Bayer Healthcare, speaker honoraria, travel/accommodation/meeting expenses; (9) Allergan, speaker honoraria, travel/accommodation/meeting expenses; (10) Celgene, travel/accommodation/meeting expenses; (11) (9) Merck, speaker honoraria, travel/accommodation/meeting expenses; (12) Bristol Meyers Squibb
(1) BMC Neuroscience, associate editor (2) Frontiers in Neurology, associate editor (3) Journal of Clinical Medicine, associate editor (4) Frontiers in Immunology, associate editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen (2) Novartis (3) Merz Pharmaceuticals (4) Ipsen (5) Roche (6) Allergan (7) Celgene
European Fund For Regional Development (EFRE.NRW)
NONE
(1) Doktor Robert Pfleger Stiftung (2) Iselore Luckow Stiftung (3) Europäischer Fonds für Forschung und Regionale Entwicklung (EFRE)
NONE
NONE
NONE
NONE
NONE
NONE
- E. Ann Yeh, MD,
I perform MS relapse adjudication for ACI services on a fee-for-service basis. Juno therapeutics scientific advisory board 2017 Biogen, scientific advisory board 2019
NONE
NONE
Neurology, editorial advisory board, 2013-present. MSJ editorial board 2016-present BMC Neurology editorial board 2016-present PLOS-One: Editorial board, 2018-present MSARD: Editorial Board 2019-present, co-chief editor 2021- present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Biogen, funding for investigator-initiated research.
1) CIHR, Co-I. PI: Pohl 2) PCORI, Co-I, CE-1304-7079 3) CMSMS (CIHI/PHAC), MS Monitoring system pilot funding 4)SCN: co-PI, 2015-present 5)OIRM, co-PI, 2015-present, PI, 2019-present
NONE
1) National MS Society HC 0148 2) National MS Society PP2256 3) MS Society (Canada) 4) Dairy Farmers of Ontario 5) SickKids Innovation Fund 6) MS Research Foundation (Canada) 7) Rare Diseases Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Shiv Saidha, MBBCh, MD, MRCPI,
Dr. Saidha has served on scientific advisory boards for Biogen, Bristol Myers Squibb, and Genentech.
NONE
NONE
I am a member of the editorial board of Multiple Sclerosis Journal and editor of Multiple Sclerosis Journal Experimental, Translational and Clinical
NONE
NONE
NONE
Consulting fees from Medical Logix for the development of CME programs in neurology, and has received equity compensation for consulting from JuneBrain LLC, a retinal imaging device developer. Have also consulted for Carl Zeiss Meditec.
NONE
NONE
NONE
Dr. Saidha is the PI of investigator-initiated studies funded by Genentech Corporation and Biogen, and was also the site investigator of a trial sponsored by MedDay Pharmaceuticals.
NONE
NONE
Dr. Saidha receives research funding from the National MS Society
NONE
NONE
NONE
NONE
NONE
NONE
- Jette Frederiksen, MD,
Novartis' Danish advisory board Merck' Danish advisory board
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Scott Douglas Newsome, DO,
Biogen Idec, scientific advisory board Genentech, scientific advisory board EMD Serono, scientific advisory board Bristol Myers Squibb, scientific advisory board Greenwich Biosciences, scientific advisory board Novartis, scientific advisory board Horizon Therapeutics, scientific advisory board medDay Pharmaceuticals, clinical adjudication committee member for a clinical trial
NONE
NONE
NONE
NONE
NONE
NONE
Autobahn BioIncept
NONE
study lead PI for a Roche clinical trial
NONE
Biogen Idec; research support payed directly to my institution and not relevant to the submitted manuscript Genentech; research support payed directly to my institution and not relevant to the submitted manuscript Roche; research support payed directly to my institution and not relevant to the submitted manuscript
NONE
NONE
National Multiple Sclerosis Society Department of Defense Patient Centered Outcomes Research Institute
NONE
NONE
NONE
NONE
NONE
NONE
- Friedemann Paul, MD;
Novartis OCTIMS study steering committee MedImmune / Viela Bio steering committee
NONE
speaker honoraria and travel grants from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, and Merck Serono, Alexion, Chugai, MedImmune, Shire, Roche, Actelion, Celgene
Academic Editor, PLoS ONE Associate Editor, Neurology Neuroimmunology and Neuroinflammation
NONE
NONE
NONE
consultancies for SanofiGenzyme, BiogenIdec, MedImmune, Shire, Alexion
NONE
NONE
NONE
Research support from from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis / Genzyme, Alexion and Merck Serono
German Research Council (DFG Exc 257), Werth Stiftung of the City of Cologne, German Ministry of Education and Research (BMBF Competence Network Multiple Sclerosis), Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program (combims.eu)
NONE
Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, National Multiple Sclerosis Society of the USA
NONE
NONE
NONE
NONE
NONE
NONE
- on behalf of IMSVISUAL
- Department of Neurosciences (J.S.G.), University of California, San Diego; Experimental and Clinical Research Center (F.C.O., F.P.), Max Delbrück Center for Molecular Medicine and Charité – Universitätsmedizin Berlin & NeuroCure Clinical Research Center, Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany; Department of neuroscience (A.V.D.W.), Central Clinical School, Monash University, Melbourne, Australia; NMR Research Unit, Queen Square MS Centre, Department of Neuroinflammation (S.C.), UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, United Kingdom; Department of Neurology (E.S.S., S.S., S.D.N.), Johns Hopkins University School of Medicine, Baltimore, MD; Rigshospitalet (J.F.), Denmark; Department of Neurology (P.A.), Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany; Division of Neurology, Department of Pediatrics (E.A.Y.), Division of Neuroscience and Mental Health, Hospital for Sick Children, Hospital for Sick Children Research Institute, and University of Toronto, Toronto, Canada.
- Correspondence
Dr. Graves jgraves{at}ucsd.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
- Article
- Abstract
- Glossary
- Afferent Visual System Anatomy
- Afferent Visual Function Measures
- Afferent Visual System Structural Measures
- Recommendations for Implementation of Afferent Assessments in Clinical Trials
- Efferent Visual System and Oculometrics
- Advantages of Assessments in the Visual System
- IMSVISUAL View of the Landscape and Proposed Role of Visual System for Trials of Agents in the Pipeline
- Study Funding
- Disclosure
- Appendix 1 Authors
- Appendix 2 Coinvestigators
- Footnotes
- References
- Figures & Data
- Info & Disclosures
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.